PE20240216A1 - Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 - Google Patents
Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2Info
- Publication number
- PE20240216A1 PE20240216A1 PE2023001361A PE2023001361A PE20240216A1 PE 20240216 A1 PE20240216 A1 PE 20240216A1 PE 2023001361 A PE2023001361 A PE 2023001361A PE 2023001361 A PE2023001361 A PE 2023001361A PE 20240216 A1 PE20240216 A1 PE 20240216A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroatoms selected
- substituted
- membered heteroaryl
- acyltransferase
- compounds
- Prior art date
Links
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 title abstract 3
- 101710167503 Diacylglycerol O-acyltransferase 2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- XNOZXMKVOLFOBL-RUZDIDTESA-N C[C@@](CC1)(CS1(=O)=O)NC(C(C=C1)=CC(N(C2=O)C(C=C3)=CC=C3F)=C1N2C(C=C1)=CC=C1F)=O Chemical compound C[C@@](CC1)(CS1(=O)=O)NC(C(C=C1)=CC(N(C2=O)C(C=C3)=CC=C3F)=C1N2C(C=C1)=CC=C1F)=O XNOZXMKVOLFOBL-RUZDIDTESA-N 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- -1 benzoimidazolone derivative compounds Chemical class 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012313 reversal agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a compuestos derivados de benzoimidazolona de formula I o sales farmaceuticamente aceptables de los mismos; en donde X, Y, Z se seleccionan independientemente entre N o C(R5); R1 es fenilo sin sustituir o sustituido con 1-3 R6, heteroarilo de 5 o 6 miembros que contiene 1-4 heteroatomos, entre otros; R2 es fenilo sin sustituir o sustituido con 1-3 R7, heteroarilo de 5 o 6 miembros que contiene 1-3 heteroatomos seleccionados de N, O y S, entre otros; R3 es heterociclilo de 4 a 7 miembros que contiene 1-3 heteroatomos seleccionados de N, O y S, heteroarilo de 5 o 6 miembros que contiene 1-3 heteroatomos seleccionados de N, O y S, entre otros; R4 es H, alquilo(C1-3), o R3 y R4 se combinan junto con el atomo de nitrogeno al que estan unidos para formar un anillo heterociclilo mono- o biciclico que contiene 1 o 2 heteroatomos seleccionados de N, O y S, en donde el anillo heterociclilo esta sin sustituir o sustituido con 1-3 R11. Un compuesto seleccionado es (R)-1,3-bis(4-fluorofenil)-N-(3-metil-1,1-dioxidotetrahidrotiofen-3-il)-2-oxo-2,3-dihidro-1H-benzo[d]imidazol-5-carboxamida. Dichos compuestos son inhibidores de diacilglicerol o-aciltransferasa 2 (DGAT2). Tambien se refiere a un metodo de preparacion de dichos compuestos, y a una composicion farmaceuticamente que los comprende, siendo utiles para prevenir, tratar o actuar como un agente de reversion para la esteatosis hepatica, esteatohepatitis no alcoholica (EHNA), fibrosis, diabetes mellitus de tipo 2, obesidad, entre otros.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063089068P | 2020-10-08 | 2020-10-08 | |
PCT/US2021/053680 WO2022076495A1 (en) | 2020-10-08 | 2021-10-06 | Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240216A1 true PE20240216A1 (es) | 2024-02-16 |
Family
ID=78500729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001361A PE20240216A1 (es) | 2020-10-08 | 2021-10-06 | Preparacion de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11976061B2 (es) |
EP (1) | EP4225739A1 (es) |
JP (1) | JP2023545741A (es) |
KR (1) | KR20230084258A (es) |
CN (1) | CN116685577A (es) |
AR (1) | AR123700A1 (es) |
AU (1) | AU2021356589A1 (es) |
CA (1) | CA3195014A1 (es) |
CL (1) | CL2023000997A1 (es) |
CO (1) | CO2023004365A2 (es) |
CR (1) | CR20230159A (es) |
DO (1) | DOP2023000069A (es) |
EC (1) | ECSP23033936A (es) |
IL (1) | IL301791A (es) |
MX (1) | MX2023003842A (es) |
PE (1) | PE20240216A1 (es) |
TW (1) | TW202229243A (es) |
WO (1) | WO2022076495A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024118858A1 (en) | 2022-12-02 | 2024-06-06 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US162818A (en) | 1875-05-04 | Improvement in brick-kilns | ||
AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
JP2001515482A (ja) | 1997-03-07 | 2001-09-18 | メタバシス・セラピューティクス・インコーポレイテッド | フルクトース−1,6−ビスホスファターゼの新規なベンズイミダゾールインヒビター |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
CN1215076C (zh) | 1998-09-09 | 2005-08-17 | 症变治疗公司 | 新的果糖1,6-二磷酸酶的杂芳族抑制剂 |
WO2003053363A2 (en) | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
EP2170883A1 (en) | 2007-06-28 | 2010-04-07 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
PE20142164A1 (es) | 2012-04-06 | 2014-12-27 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
AR098394A1 (es) | 2013-11-25 | 2016-05-26 | Lilly Co Eli | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) |
AP2016009407A0 (en) | 2014-03-17 | 2016-08-31 | Pfizer | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders |
WO2016036638A1 (en) | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
EP3188732B1 (en) | 2014-09-05 | 2019-07-24 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
EP3188730B1 (en) | 2014-09-05 | 2019-05-01 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
SG10202006563PA (en) | 2015-07-10 | 2020-08-28 | Ionis Pharmaceuticals Inc | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
JP2020502058A (ja) | 2016-11-18 | 2020-01-23 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ジアシルグリセリドo−アシルトランスフェラーゼ2の阻害薬として有用なインダゾール誘導体 |
RU2019117958A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶2 抑制劑 |
-
2021
- 2021-10-06 AR ARP210102766A patent/AR123700A1/es unknown
- 2021-10-06 US US17/494,906 patent/US11976061B2/en active Active
- 2021-10-06 AU AU2021356589A patent/AU2021356589A1/en active Pending
- 2021-10-06 CA CA3195014A patent/CA3195014A1/en active Pending
- 2021-10-06 WO PCT/US2021/053680 patent/WO2022076495A1/en active Application Filing
- 2021-10-06 JP JP2023521375A patent/JP2023545741A/ja active Pending
- 2021-10-06 IL IL301791A patent/IL301791A/en unknown
- 2021-10-06 EP EP21802077.4A patent/EP4225739A1/en active Pending
- 2021-10-06 CN CN202180082235.8A patent/CN116685577A/zh active Pending
- 2021-10-06 MX MX2023003842A patent/MX2023003842A/es unknown
- 2021-10-06 TW TW110137150A patent/TW202229243A/zh unknown
- 2021-10-06 KR KR1020237015525A patent/KR20230084258A/ko unknown
- 2021-10-06 CR CR20230159A patent/CR20230159A/es unknown
- 2021-10-06 PE PE2023001361A patent/PE20240216A1/es unknown
-
2023
- 2023-04-05 CO CONC2023/0004365A patent/CO2023004365A2/es unknown
- 2023-04-05 DO DO2023000069A patent/DOP2023000069A/es unknown
- 2023-04-05 CL CL2023000997A patent/CL2023000997A1/es unknown
- 2023-05-08 EC ECSENADI202333936A patent/ECSP23033936A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US11976061B2 (en) | 2024-05-07 |
EP4225739A1 (en) | 2023-08-16 |
AR123700A1 (es) | 2023-01-04 |
CR20230159A (es) | 2023-06-02 |
CO2023004365A2 (es) | 2023-04-17 |
CL2023000997A1 (es) | 2023-10-06 |
MX2023003842A (es) | 2023-04-14 |
DOP2023000069A (es) | 2023-05-15 |
JP2023545741A (ja) | 2023-10-31 |
AU2021356589A1 (en) | 2023-05-25 |
KR20230084258A (ko) | 2023-06-12 |
WO2022076495A1 (en) | 2022-04-14 |
CA3195014A1 (en) | 2022-04-14 |
TW202229243A (zh) | 2022-08-01 |
US20220112182A1 (en) | 2022-04-14 |
CN116685577A (zh) | 2023-09-01 |
IL301791A (en) | 2023-05-01 |
ECSP23033936A (es) | 2023-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
AR065015A1 (es) | Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR075321A1 (es) | Compuestos de amidina sustituida para combatir plagas de animales | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
PE20040832A1 (es) | Derivados de indolil pirazinona | |
CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
ES2548998T3 (es) | Composiciones antifúngicas de azol | |
AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
AR061873A1 (es) | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. | |
PE20090042A1 (es) | Analogos de ciclopamina | |
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
PE20090477A1 (es) | Derivados de oxazol como inhibidores de los canales de sodio | |
AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
ECSP088397A (es) | Derivados de amida heterociclica útiles como microbiocidas | |
AR041009A1 (es) | Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
EA201170522A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств |